REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton...
https://pubmed.ncbi.nlm.nih.gov/33332778/Actively Recruiting
Led by Federal University of Minas Gerais · Updated on 2026-09-15
120
Participants Needed
2
Research Sites
26 weeks
Total Duration
Researchers are evaluating Resomelagon as a potential treatment for adults with Dengue virus infection. This randomized, double-blind, placebo-controlled Phase 2a trial aims to understand if Resomelagon is safe to use in dengue patients and whether it can reduce the duration of illness. The study is based on prior research showing anti-inflammatory and pro-resolving effects of Resomelagon in animal models and COVID-19 patients, suggesting it may help decrease disease severity and inflammatory responses in dengue. Participants will be randomly assigned to receive either Resomelagon 100mg orally once daily plus standard treatment or a placebo plus standard treatment. The standard treatment includes hydration and symptomatic therapy as needed for dengue fever. The study is designed to compare these groups over the treatment period to evaluate safety and efficacy. During the trial, participants will take the assigned medication and undergo blood tests to monitor their health and response. Researchers will assess safety over 28 days and measure how Resomelagon affects the duration and severity of illness, plasma leakage, and hospitalization rates within 10 days. The study includes careful monitoring of clinical and laboratory criteria to evaluate outcomes, with the entire participation lasting up to about a month.
CONDITIONS
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
P
Pedro RJ Almeida, MD MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Federal University of Minas Gerais
Lead Sponsor
Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 10 days
Participants take either Resomelagon 100mg orally once daily or a placebo, along with standard dengue treatment including hydration and symptom relief.
Daily medication with periodic blood tests and clinical evaluations
Duration - 28 days
Participants are monitored for safety and illness duration outcomes for up to 28 days after treatment begins.
Regular safety assessments and blood tests
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
David M Weinreich, Sumathi Sivapalasingam, Thomas Norton...
https://pubmed.ncbi.nlm.nih.gov/33332778/Mohd Imran, Mandeep Kumar Arora, Syed Mohammed Basheeruddin Asdaq...
https://pubmed.ncbi.nlm.nih.gov/34641339/Awadhesh Kumar Singh, Akriti Singh, Ritu Singh...
https://pubmed.ncbi.nlm.nih.gov/34742052/Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner...
https://pubmed.ncbi.nlm.nih.gov/35172054/Podjanee Jittamala, William H K Schilling, James A Watson...
https://pubmed.ncbi.nlm.nih.gov/37470445/Monaíse M O Silva, Mariana Kikuti, Rosângela O Anjos...
https://pubmed.ncbi.nlm.nih.gov/33684559/Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie...
https://pubmed.ncbi.nlm.nih.gov/36566761/William H K Schilling, Podjanee Jittamala, James A Watson...
https://pubmed.ncbi.nlm.nih.gov/37778363/Peter Chen, Ajay Nirula, Barry Heller...
https://pubmed.ncbi.nlm.nih.gov/33113295/Pedro R J Almeida, Alexandre M Periard, Fernanda L Tana...
https://pubmed.ncbi.nlm.nih.gov/39159951/Federal University of Minas Gerais
Lead Sponsor
Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)
Collaborating Sponsor